Despite well-established correlations between immune cell infiltrate, prognosis, and the demonstrated antigenicity of multiple tumor-associated targets (e.g., NY-ESO-1, Mesothelin, Her2/Neu, TP53, MUC16 and others [3,4,5,6]), clinical trials targeting these antigens have shown very limited efficacy [2]. This evidence concerns the gene ERBB2 and neoplasm.